Press release
Glioblastoma Multiforme Treatment (GBM) Market Projected to Reach US$0.91 bn in 2022
A new report published by Transparency Market Research on the global glioblastoma treatment market provides insights into the growth drivers, potential restraints, and growth opportunities that the market is likely to witness between 2014 and 2022. The report is titled “Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022” and is available for sale in the company website. The market, according to the report, will grow from a valuation of US 0.34 bn in 2013 to US$0.91 bn in 2022, exhibiting a positive CAGR of 11.40% during the period
Read Report overview @ https://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html
The Global Glioblastoma Multiforme Treatment (GBM) Market is segmented on the basis of expression system, product type,by Geography, by Drugs , end user and region.
According to the report, rising awareness regarding the types of brain tumors, increased funding for R&D in drug delivery technologies, and the introduction of modern diagnostic techniques fuel the market for glioblastoma treatment. Among the available modalities, in 2013, the glioblastoma treatment market was dominated by temozolomide. However, the drug recently lost its patent, allowing generic drugs to foray into the market and significantly bring down the market share of temozolomide.
The geographical segmentation of GBM market comprises North America, Europe, Asia Pacific and Rest of the World. Bevacizumab (Avastin) is the latest addition to this artillery, while temozolomide was leading the GBM market in 2013 due to it’s effectiveness when combined with surgery. Bevacizumab is the first monoclonal antibody drug approved for GBM treatment which is more efficient than temozolomide and is expected to surpass its revenue by 2016. Temozolomide market was drastically affected in 2013 as it has lost the market exclusivity in 2012 and generics manufactured by Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. entered the market. Geographically, in 2013 North America was observed as the most leading GBM market due to increasing support from government and non-government organizations to raise public awareness by and advanced healthcare infrastructure to boost the pipeline research in this market. Asia Pacific is the fastest growing market, rising awareness against GBM is boosting the diagnostic rate in this region and developing healthcare infrastructure is also assisting the market growth.
Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4807
Summary of Table of Content:
1 Preface
2 Executive Summary
3 Market Overview
4 Global Pipeline Review of Glioblastoma Treatment
5 Recommendations
6 Company Profiles
Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/4807
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Treatment (GBM) Market Projected to Reach US$0.91 bn in 2022 here
News-ID: 869233 • Views: …
More Releases from Transparency Market Research
Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive A …
The global Neuromorphic Chip Market is entering a defining phase of exponential growth, propelled by a surge in artificial intelligence (AI) applications, edge computing expansion, and rapid advancements in next-generation semiconductor technologies. According to the latest industry analysis, the market-valued at US$ 56.2 Mn in 2023-is projected to expand at an extraordinary CAGR of 40.1% from 2024 to 2034, reaching an estimated US$ 2.3 Bn by 2034.
Examine key highlights and…
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological …
The global Neuroprotection Market continues to gain unprecedented momentum as healthcare systems worldwide intensify their focus on combating neurological disorders. With a valuation of US$ 31.6 Bn in 2022, the market is on track to reach US$ 60.1 Bn by 2031, expanding at a robust 7.5% CAGR during the forecast period. The rise in dementia, stroke, Parkinson's, epilepsy, and multiple sclerosis-combined with aging demographics and a surge in sedentary lifestyles-has…
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Inn …
The global neuroregeneration therapy market continues to chart steady, sustained growth. The increasing incidence of neurological disorders-including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, stroke, diabetic neuropathy, and spinal cord injuries-is significantly influencing market expansion. In 2023, the market was worth US$ 37.0 Bn, demonstrating rising demand for treatments capable of repairing or regenerating damaged neural tissue.
Examine key highlights and takeaways from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86322
With breakthroughs…
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Adv …
The global neuroscience market stood at US$ 30.1 Bn in 2022, reflecting the significant technological and clinical potential of neurological research. Projected to grow at a CAGR of 3.7% from 2023 to 2031, the industry is expected to reach US$ 41.6 Bn by 2031. Rising prevalence of neurodegenerative diseases, advancements in neuroimaging, integration of artificial intelligence, and the emergence of brain-computer interfaces are shaping the next decade of neuroscience innovation.
Examine…
More Releases for GBM
Glioblastoma Multiforme (GBM) Treatment Market Report 2024: Trends and Projectio …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.66 billion In…
Goodpasture Syndrome (Anti-GBM Disease) With Excellent CAGR 5.30%
Goodpasture Syndrome Treatment market analysis report is a professional and a detailed market study focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. This market report is a comprehensive background analysis of the ABC industry, which includes an assessment of the parental market. The report also aids in prioritizing market goals and attain profitable business. This analysis gives an examination of various segments that are relied…
Anti-GBM Autoantibody Disease Market - Embracing Immune Harmony: Anti-GBM Autoan …
Newark, New Castle, USA - new report, titled Anti-GBM Autoantibody Disease Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-GBM Autoantibody Disease market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-GBM Autoantibody Disease market. The report offers an overview of…
Glioblastoma Multiforme Treatment (GBM) Market: Trends, Opportunities & Regional …
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and…
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
